The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clin. approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic anal. of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compd. BO1 (I) shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.

Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms

SCHENONE, SILVIA;
2010

Abstract

The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clin. approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic anal. of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compd. BO1 (I) shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.
File in questo prodotto:
File Dimensione Formato  
bmc 2010, 18, 3999.pdf

non disponibili

Tipologia: Documento in versione editoriale
Dimensione 950.13 kB
Formato Adobe PDF
950.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11567/294028
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact